Skip to main content

Table 1 Baseline screening, assessment, and follow-up schedule

From: Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial

  At baseline Time after surgery Early withdrawal
14 days 21 days 28 days 3 months 6 months 12 months 18 months 24 months
Follow-up time window (days)   ±2 ±2 ±2 ±7 ±7 ±7 ±7 ±7  
Informed consent          
Demographic characteristics          
Socioeconomic status          
Medical history          
Information on tumor clinical evaluation and surgical operation          
Physical examination          
Blood routine examination      
Blood clotting function          
Routine urine test      
Routine stool test      
Blood biochemistry      
Hormone testinga    
Tumor biomarkersb    
Gynecological examinationc    
Abdominal/pelvic CT/MRI
Chess X-ray     
Assessment of residual urined      
Urodynamic tests           
Anorectal function evaluation           
Pelvic floor functional testing          
Adverse events    
  1. : Indicates mandatory items
  2. ▲: Investigator will decide whether to perform the testi according to clinical signs or clinical evaluation
  3. aHormone testing includes estradiol, progesterone, testosterone, prolactin, follotropin and luteinizing hormone
  4. bTumor biomarkers includes squamous cell carcinoma antigen, CA125, CA199 and carcinoembryonic antigen
  5. cGynecological examination includes Human Papillomavirus and Thinprep Cytological Testing
  6. dResidual urine is evaluated by B ultrasound
  7. eEQ-5D: European Quality of Life-5 Dimensions
  8. fPISQ-12: Prolapse/Urinary Incontinence Sexual Questionnaire short form
  9. gPFDI-20: Pelvic Floor Distress Inventory
  10. hICIQ/OABss: International Consultation on Incontinence Questionnaire/Overactive Bladder Symptom Score